{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:02:05Z","timestamp":1784941325766,"version":"3.55.0"},"reference-count":48,"publisher":"Georg Thieme Verlag KG","funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024A1515010811"],"award-info":[{"award-number":["2024A1515010811"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Previous clinical studies have indicated that Keluoxin can be used for the treatment of diabetic kidney disease. However, the specific mechanisms involved and the primary effective components have not been fully explored.<\/jats:p>\n                  <jats:p>Purpose The purpose of this study was to investigate the protective mechanisms of Keluoxin and its main components against diabetic kidney disease.<\/jats:p>\n                  <jats:p>Methods The animal models included db\/db mice treated with Keluoxin or saline and db\/m mice treated with saline. Astragaloside IV was used to treat human kidney-2 cells for in vitro experiments. To assess the effects of Keluoxin on diabetic kidney disease, serum biochemical parameters and tissue histopathological staining were examined. Western blotting and the quantitative real-time polymerase chain reaction were employed to detect the expression levels of fibrosis and inflammation markers. RNA sequencing was conducted on the samples, and downstream mechanisms were validated at the level of animal tissues and cells.<\/jats:p>\n                  <jats:p>Results Keluoxin significantly reduced blood glucose and urinary microalbumin in db\/db mice, alleviated renal tubular damage, inflammation and fibrosis in diabetic kidney disease mice, and did not cause any damage to liver function. Sequencing results indicated that Keluoxin modulated the tumor necrosis factor signaling pathway, nuclear factor kappa light chain enhancer of activated B cell signaling pathway and inflammatory responses. In vivo experiments showed that Keluoxin inhibits the tumor necrosis factor alpha\/inhibitor of kappa B kinase beta\/inhibitor of nuclear factor kappa B alpha\/nuclear factor kappa light chain enhancer of activated B cell p65 pathway, thereby providing protection against diabetic kidney disease. Immunoinfiltration analysis indicated that Keluoxin reduced neutrophil infiltration in the renal cortex of diabetic kidney disease mice. Through pharmacological component analysis, we determined that astragaloside IV is the main component of Keluoxin. In vitro experiments showed that astragaloside IV also alleviated the inflammatory response and fibrosis, inhibiting the expression of the tumor necrosis factor alpha\/inhibitor of kappa B kinase beta\/inhibitor of nuclear factor kappa B alpha\/nuclear factor kappa light chain enhancer of activated B cell p65 signaling pathway.<\/jats:p>\n                  <jats:p>Conclusions Keluoxin exerts renal protective effects by inhibiting the tumor necrosis factor alpha\/inhibitor of kappa B kinase beta\/inhibitor of nuclear factor kappa B alpha\/nuclear factor kappa light chain enhancer of activated B cell p65 signaling pathway with astragaloside IV being the primary active component.<\/jats:p>","DOI":"10.1055\/a-2911-9625","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:55:08Z","timestamp":1783724108000},"source":"Crossref","is-referenced-by-count":0,"title":["Keluoxin inhibits the progression of Diabetic Kidney Disease via TNF-\u03b1\/IKK\u03b2\/I\u03baB\u03b1\/NF-\u03baB p65 signaling pathway"],"prefix":"10.1055","author":[{"given":"Hanrong","family":"Zhang","sequence":"first","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlu","family":"Xiao","sequence":"first","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]},{"name":"Guangdong General Hospital, China","place":["Guangzhou"],"department":["Department of Nephrology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Ye","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Luo","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Jia","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Ma","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongji","family":"Zheng","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Xue","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-4780","authenticated-orcid":false,"given":"Yaoming","family":"Xue","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangdong, China","place":["Guangzhou"],"department":["Department of Endocrinology & Metabolism"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1053\/j.ajkd.2016.11.018","article-title":"Diabetes control and the risks of ESRD and mortality in patients with CKD","volume":"70","author":"S D Navaneethan","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e165654","DOI":"10.1172\/jci165654","article-title":"Molecular pathways that drive diabetic kidney disease","volume":"133","author":"S Mohandes","year":"2023","journal-title":"J Clin Invest"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/ijms24010570","article-title":"What\u2019s new in the molecular mechanisms of diabetic kidney disease: Recent advances","volume":"24","author":"K Watanabe","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"R Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"HJ L Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"S C Palmer","year":"2021","journal-title":"Bmj"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"G L Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"E W Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1016\/j.apsb.2020.12.020","article-title":"Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management","volume":"11","author":"G Tang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1052852","DOI":"10.3389\/fphar.2022.1052852","article-title":"Efficacy and safety of Keluoxin capsule in combination with Western medicine for diabetic kidney disease: A systematic review and meta-analysis","volume":"13","author":"W Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/jicm.2022.0809","article-title":"A prospective, multicentered, randomized, double-blind, placebo-controlled clinical trial of keluoxin capsules in the treatment of microalbuminuria in patients with type 2 early diabetic kidney disease","volume":"30","author":"J Zhao","year":"2024","journal-title":"J Integr Complementary Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8455709","DOI":"10.1155\/2021\/8455709","article-title":"Protective effect of keluoxin against diabetic nephropathy in type 2 diabetic mellitus models","volume":"2021","author":"X Yang","year":"2021","journal-title":"Evidence-Based Complementary Altern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/jrr\/rrad050","article-title":"Combining network pharmacology and in vitro and in vivo experiments to study the mechanism of Keluoxin in the treatment of radiation nephropathy","volume":"64","author":"L Deng","year":"2023","journal-title":"J Radiat Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1039\/d0ra00343c","article-title":"Identification of key lipid metabolites during metabolic dysregulation in the diabetic retinopathy disease mouse model and efficacy of Keluoxin capsule using an UHPLC-MS-based non-targeted lipidomics approach","volume":"11","author":"N Ge","year":"2021","journal-title":"RSC Adv"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"156776","DOI":"10.1016\/j.phymed.2025.156776","article-title":"Keluoxin reduces renal lipid deposition in diabetic nephropathy via AMPK\/NF-\u03baB-mediated mtabolic regulation","volume":"145","author":"S Zhang","year":"2025","journal-title":"Phytomedicine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20190987","article-title":"Astragaloside IV attenuates high glucose-induced EMT by inhibiting the TGF-\u03b2\/Smad pathway in renal proximal tubular epithelial cells","volume":"40","author":"Y N Wang","year":"2020","journal-title":"Biosci Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41420-022-00848-2","article-title":"Blocking GSDME-mediated pyroptosis in renal tubular epithelial cells alleviates disease activity in lupus mice","volume":"8","author":"G Luo","year":"2022","journal-title":"Cell Death Discov"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325334","article-title":"TNFAIP9 protects against the development of the early stage of chronic kidney disease: Focus on inflammation and fibrosis","volume":"20","author":"Y Chen","year":"2025","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jare.2024.09.021","article-title":"DeSUMOylation of RBMX regulates exosomal sorting of cargo to promote renal tubulointerstitial fibrosis in diabetic kidney disease","volume":"74","author":"Y Yang","year":"2024","journal-title":"J Adv Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"C340","DOI":"10.1152\/ajpcell.00167.2018","article-title":"Early growth response protein-1 upregulates long noncoding RNA Arid2-IR to promote extracellular matrix production in diabetic kidney disease","volume":"316","author":"Y L Yang","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"728256","DOI":"10.3389\/fphar.2022.728256","article-title":"Chinmedomics strategy for elucidating the pharmacological effects and discovering bioactive compounds from keluoxin against diabetic retinopathy","volume":"13","author":"L Kong","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref23","first-page":"780","article-title":"[KeLuoXin medicated serum extract inhibits high glucose-induced proliferation and phosphorylation of ERK1\/2 in rat mesangial cell]","volume":"41","author":"L Li","year":"2010","journal-title":"Sichuan Daxue Xuebao, Yixueban"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"G D Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: A road to inflammation","volume":"23","author":"G van Loo","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"re13","DOI":"10.1126\/stke.3572006re13","article-title":"Regulation and function of IKK and IKK-related kinases","volume":"2006","author":"H H\u00e4cker","year":"2006","journal-title":"Sci STKE"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"a000158","DOI":"10.1101\/cshperspect.a000158","article-title":"The IKK complex, a central regulator of NF-kappaB activation","volume":"2","author":"A Isra\u00ebl","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/ni.2055","article-title":"Return to homeostasis: Downregulation of NF-\u03baB responses","volume":"12","author":"J Ruland","year":"2011","journal-title":"Nat Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"O Takeuchi","year":"2010","journal-title":"Cell"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: Mechanism and clinical study","volume":"5","author":"H Yu","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"154740","DOI":"10.1016\/j.metabol.2021.154740","article-title":"Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2\/NF-\u03baB pathway","volume":"119","author":"H Wang","year":"2021","journal-title":"Metabolism"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmet.2019.02.007","article-title":"Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-\u03baB\/TNF-\u03b1 pathway","volume":"23","author":"H Yang","year":"2019","journal-title":"Mol Metab"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.kint.2022.08.026","article-title":"The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease","volume":"102","author":"J Fu","year":"2022","journal-title":"Kidney Int"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e126453","DOI":"10.1172\/jci.insight.126453","article-title":"Single cell transcriptomics based-MacSpectrum reveals novel macrophage activation signatures in diseases","volume":"5","author":"C Li","year":"2019","journal-title":"JCI Insight"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/biomedicines11071889","article-title":"Relationship between macrophages and tissue microenvironments in diabetic kidneys","volume":"11","author":"J Yan","year":"2023","journal-title":"Biomedicines"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2174\/1566523218666180214100351","article-title":"Role of immune cells in diabetic kidney disease","volume":"17","author":"X Yang","year":"2017","journal-title":"Curr Gene Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.3390\/ijms25084476","article-title":"Research progress on anti-inflammatory effects and related mechanisms of astragalin","volume":"25","author":"J Ruan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.3390\/molecules28166118","article-title":"Pharmacological effects of astragaloside IV: A review","volume":"28","author":"Y Liang","year":"2023","journal-title":"Molecules"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/ptr.2434","article-title":"Astragaloside IV attenuates lipolysis and improves insulin resistance induced by TNFalpha in 3T3-L1 adipocytes","volume":"22","author":"B Jiang","year":"2008","journal-title":"Phytother Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13046-023-02643-y","article-title":"Correction: Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling","volume":"42","author":"F Xu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2147\/dddt.S399423","article-title":"The molecular basis of the anti-inflammatory property of astragaloside IV for the treatment of diabetes and its complications","volume":"17","author":"L Li","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.cyto.2013.01.008","article-title":"Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-\u03baB-mediated inflammatory genes expression","volume":"61","author":"D Gui","year":"2013","journal-title":"Cytokine"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3892\/ijmm.2014.1741","article-title":"Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase\/ROS\/Akt\/NF\u2011\u03baB pathway under high glucose conditions","volume":"34","author":"L Sun","year":"2014","journal-title":"Int J Mol Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3892\/ijmm.2021.4996","article-title":"Astragaloside IV ameliorates diabetic nephropathy in db\/db mice by inhibiting NLRP3 inflammasome\u2011mediated inflammation","volume":"48","author":"H Feng","year":"2021","journal-title":"Int J Mol Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Y Liu","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: The master regulator of fibrosis","volume":"12","author":"X M Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature11862","article-title":"Metabolism of inflammation limited by AMPK and pseudo-starvation","volume":"493","author":"L A O\u2019Neill","year":"2013","journal-title":"Nature"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: Molecular activation and regulation to therapeutics","volume":"19","author":"K V Swanson","year":"2019","journal-title":"Nat Rev Immunol"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2911-9625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:30:59Z","timestamp":1784939459000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2911-9625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1055\/a-2911-9625","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,10]]},"published":{"date-parts":[[2026,7,10]]}}}